Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Background: The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis. Methods: This meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used. Results: Thirteen randomised clinical trials were considered eligible ( n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD −0.56; 95% CI −0.69 to −0.43, I 2 92%) or the control group (SMD −0.45; 95% CI −0.68 to −0.23, I 2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust. Conclusion: The present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events. Systematic Review Registration: PROSPERO [CRD42024500551].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, several trials have reported reductions in CRP and related biomarkers with GLP‐1RA therapy [11, 12]”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464 · cited 1×
“Statistical software R (version 3.5.1) was used for the analysis (23).”
MethodInfluentialWan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“The 95% CIs were calculated manually when not reported in the original publications (22).”
MethodSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“Accordingly, the anti-in fl ammatory mechanisms associated with GLP-1RA treatment could be closely linked to the cardiovascular bene fi t seen in clinical trials (7, 10).”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 6×
“Thirteen randomised clinical trials ( n = 26,131 patients) were identi fi ed and considered eligible for this systematic review (10, 24 – 35).”
BackgroundMethodInfluentialC-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Research works printed but not linked: 1
- White-Flowers, 2010, Obesity as an inflammatory process, Bol Med Hosp Infant Mex, 67, 88
Cited by
Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00459-9 · Cited by 110
Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns
(2025) · The American Journal of Managed Care · doi:10.37765/ajmc.2025.89778 · Cited by 65
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 56
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 40
“…studies have observed a decrease in pro-inflammatory markers during use of a GLP-1RA, and an anti-inflammatory effect has been considered to contribute to the pleiotropic properties of these agents across metabolic, cardiorenal, neuro-degenerative, osteoarthritic and other diseases [47,68,69].”
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“…review and meta-analysis of 13 RCTs involving 26,131 participants reported a significant decrease in CRP levels with semaglutide compared to placebo (standardized mean difference [SMD] −0.56; 95% CI: −0.69 to − 0.43) and other glucose-lowering drugs (SMD −0.45; 95% CI: −0.68 to − 0.23) [111].”
InfluentialAnti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09991-4 · Cited by 21
Self-citationMasson, W. M., Villar, G. M. F., & Elhelou, S. M. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03154-2 · Cited by 18
Self-citationTherapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Nowak, K., Łupina, K., Romac, A., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251322002 · Cited by 21
“31 The gut microbiota plays a crucial role in MASLD development by regulating energy balance, lipid metabolism, and inflammation through mechanisms such as bile acid metabolism and endotoxin production.”
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 17
“…of its glucose-lowering effects [33] and have been observed in obese patients with high cardiovascular risk without diabetes at high doses [32]. the cardiovascular benefits of semaglutide are attributed to direct cardiac effects (protection against myocardial ischemia, reduction of…”
InfluentialMeyhöfer, S. M., Cariou, B., Cercato, C., Colhoun, H. M., Deanfield, J. E., Long, M. T., Jeppesen, O. K., Lincoff, A. M., Lingvay, I., Plutzky, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04281-1 · Cited by 13
“Semaglutide has been shown to reduce markers of systemic inflammation, for example, high-sensitivity C-reactive protein 22 and tissue-specific inflammation in the liver 23 and heart 24–26 , and increases the secretion of adiponectin, an insulin-sensitizing adipokine 27 .”
Muscle health in the modern era of incretin‐based therapies
Girolamo, G. D., Sangineto, M., Gioia, G. D., Bianco, R., Ciarnelli, M., & Serviddio, G. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70155 · Cited by 16
“12,13 However, while the benefits of significant FM loss are well established, concerns have been raised regarding the potential unintended loss of SMM and physical function associated with GLP- 1RA-induced weight reduction.”
Kitsunai, H., Shinozaki, Y., Furusawa, S., Kitao, N., Ito, M., Kurihara, H., Oba‐Yamamoto, C., Takeuchi, J., Nakamura, A., Takiyama, Y., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18010129 · Cited by 11
Saeed, A., Mulukutla, S. R., Thoma, F. W., Lemon, L. S., Koczo, A., Reís, S. E., Marroquin, O. C., & Kip, K. E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-00775 · Cited by 10
Huang, Y., Chen, J.-C., Li, P., Hsu, M., Cheng, C., Meyerowitz‐Katz, G., & Su, P. (2025) · Communications Medicine · doi:10.1038/s43856-025-01066-4 · Cited by 11
GLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 14
“Additional mechanistic biomarker studies report improved insulin signaling and reduced plasma inflammatory markers following GLP-1RA therapy, pointing toward systemic pathways that may underlie cognitive resilience (Gonzalez-Rellan and Drucker 2025; Masson et al. 2024; Mashayekhi et al. 2024).”
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031186 · Cited by 11
“Importantly, several of these effects—such as reductions in visceral adiposity, normalization of adipokine profiles, and suppression of adipose inflammation—cannot be fully explained by weight loss alone, underscoring the presence of direct and indirect adipose-specific mechanisms [47,67,68].”
Metabolite and nutrient regulation of macrophages in obesity and metabolic disease
Sprenkle, N. T., & Mills, E. L. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01292-4 · Cited by 14
“…possibility that other commercially popular weight-loss drugs such as semaglutide that have anti-inflammatory effects on cultured immune cells in animal models and in humans 144,145 may modulate the levels of metabolites that rewire immune cell function and potentiate their anti-diabetic effects.”
Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging
Ortiz, G. U., & de Freitas, E. C. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102582 · Cited by 10
Adipose immune microenvironment: catalyst of age-related adipose tissue dysfunction
Song, Y., Xing, H., Luo, Y., Li, B., Li, Y., & Dong, Z. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00545-5 · Cited by 10
“It also reduces chronic inflammation by activating GLP-1R on immune cells and inhibiting NF-κB signaling pathway [288, 289].”
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 10
Bruno, A., Schirosi, M., & Foti, R. (2026) · Aesthetic Plastic Surgery · doi:10.1007/s00266-026-05805-3 · Cited by 6
“This rigorous selection protocol was implemented to ensure patient safety and scientific validity, enabling reliable comparison between the pharmacologic and lifestyle cohorts with respect to perioperative inflammatory and thrombotic responses (Tables 1, 2, 3, 4, 5, 6, 7, and 8).”
Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial
Atieh, O., Daher, J., Abboud, M., Wu, Q., Sattar, A., Baissary, J., Koberssy, Z., Labbato, D. E., Eckard, A. R., & McComsey, G. A. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf577 · Cited by 9
Gaelzer, G. C., Prata, A. A., Rizzolli, L. G., Afonso, L., & Marques, G. L. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103194 · Cited by 5
Impact of medical versus surgical weight loss on cardiovascular outcomes
Ostapenko, A., & Ahmed, B. H. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.03.004 · Cited by 5
Bolek, T., Turňová, P., Jánošová, S., Péč, M. J., Ságová, I., Nagy, N., Jurica, J., Mokáň, M., & Samoš, M. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.102885 · Cited by 7
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Luca, L. D., Bilato, C., Navazio, A., Corda, M., Milli, M., Scicchitano, P., Marco, M. D., Riccio, C., Geraci, G., Iacovoni, A., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf071 · Cited by 4
“35,36 The GLP-1R IEL is required to transduce the local and systemic anti-inflammatory actions of GLP-1 when inflammation is induced through T-cell activation, for example, using antibodies that target the CD3 T-cell co-receptor.”
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Overweight and obesity in metabolic syndrome
Nedogoda, S. V., & Васильевна, Ц. О. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6535 · Cited by 5
Abdullah, A., Sagreeka, F. N. U., Aniket, G. A., Lal, R., Geeta, F. N. U., Bai, A., Ahmed, G. U., Raza, A. A., Shaikh, V. F., Sanaullah, O., et al. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70136 · Cited by 3
Minerva, F. (2025) · Bioethics · doi:10.1111/bioe.70068 · Cited by 8
Samuel, A. H., Kshatri, A. H. S., Babu, R. N., Patel, H. S., Viswanathan, S. H., Challa, M. S. R., & Swathi, N. L. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102494 · Cited by 4
The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma
Chen, H., Elhawi, M. A., & Tarbox, M. B. (2025) · Cureus · doi:10.7759/cureus.88725 · Cited by 4
“These anti-inflammatory and anti-fibrotic effects have also been observed in metabolic conditions, particularly cardiovascular disease [9].”
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
Chopra, H., Mehta, A., Ponde, C., Nanda, N. C., Wander, G., Oomman, A., KERKAR, D. P., Routray, S., Ratnaparkhi, G., Advani, P., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1375 · Cited by 2
Li, J., Cao, B., Yu, S., Li, C., Xue, M., xie, Q., Luo, C., Duan, C., Li, Z., & Jin, C. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s610406 · Cited by 4
“100 At the joint level, preclinical studies indicate that GLP-1R is expressed in chondrocytes and synovial macrophages; liraglutide has been reported to suppress iNOS, MMP-13, and ADAMTS-5 and to attenuate hypersensitivity in inflammatory pain models, suggesting potential anti-inflammatory and…”
Nonischemic Cardiomyopathy in Adult-Onset PPA2-Deficient Mitochondrial Disease
Théberge, E. T., Code, J., Khoo, J. K., Lai, C., Ignaszewski, A., Virani, S., Toma, M., Roston, T. M., Sedlak, T., & Lehman, A. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.104676 · Cited by 1
Dayel, F. F. B., Alanazi, R. J., Alenazi, M. A., Alkhalifah, S., Dayel, D. F. B., Mawkili, W., & Alwhaibi, A. M. (2026) · Healthcare · doi:10.3390/healthcare14070845 · Cited by 1
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Jiang, T., Wan, T.-H., Wang, M., Zhu, X.-Q., Jiang, Y., Yang, F., Ling, Z.-C., Tan, X.-Y., Wang, J., & Ouyang, N. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103231 · Cited by 2
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Lama, S., Chaudhuri, S., Blankenship, D. M., Ban, A. N., Usvyat, L. A., Pecoits-Filho, R., & Hippen, B. E. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101476 · Cited by 1
Anaspure, O. S., Sivaram, P., Guruprasad, P., Anaspure, A. S., Kadakia, R. J., & Anastasio, A. T. (2026) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2026.07.011 · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“Decreases in inflammatory markers, including high-sensitivity C-reactive protein, interleukin-6, and tumor necrosis factor alpha, have been reported, suggesting attenuation of chronic low-grade inflammation associated with obesity [229,230].”
Guo, J., Bachor, T. P., Takahashi, R., Steffek, M., Fitzgerald, G. A., Huffman, B. J., Braun, D., Han, S. J., Sandmann, T., Ha, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.06.680810 · Cited by 2
Author Reply to The semaglutide paradox in non-overweight diabetes: a benefit without explanation
Kishimori, T., & Kato, T. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf090
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 3
Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation
Bojórquez-González, A. Y., Gómez-Sánchez, E., Suárez-Rico, D. O., Beltrán-Ramírez, A., Balleza-Alejandri, L. R., López-Murillo, L. D., Ramírez-Lizardo, E. J., & García-Galindo, J. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083694
Fouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Oyewole, S. O., & Owosho, A. A. (2026) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2026.06.002 · Cited by 3
Effect of semaglutide on measured versus estimated glomerular filtration rate
Yahya, R., Iversen, E., Sivalingam, S., Christensen, L. W. S., Persson, F., Hansen, T. W., Hornum, M., Rossing, P. R., Curovic, V. R., & Houlind, M. B. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag154
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Jargiło, M., Kucza, J., & Mrukwa–Kominek, E. (2026) · Ophthalmology · doi:10.5114/oku/226459
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Cummings, J. L., & Scheltens, P. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100677 · Cited by 1
“This biomarker is elevated in T2D and is reduced with treatment in trials of semaglutide in diabetic patients [10,11].”
Systemic Inflammation and Adverse Heart Failure Outcomes
Sandhu, A. T., Furst, A., Varshney, A. S., Sallam, K., Hsiao, S., Gromovsky, A., Khachatourian, K. W., Din, N., Skaar, J. R., & Tonnu-Mihara, I. Q. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103346
Schwartzberg, E., Berman, E., Shani, S., Azran, C., Hagoel, R., Diker‐Cohen, T., & Dotan, I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2756017
Semaglutide and cardio-renal protection: Mechanistic insights from FLOW, SELECT and the NHE3 paradox
Kabir, A., Mouree, T. Z., Das, M., & Joy, F.-U.-H. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261503097
Metadata
- Authors
- Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D.
- Affiliations
- Hospital Italiano de Buenos Aires (AR)
- Universidad Internacional de las Américas (CR)
- Sanatorio Otamendi y Miroli (AR)
- Corresponding author
- Masson, Walter
- ORCID
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2024-07-05
- Volume
- 11
- Pages
- 1379189-1379189
- ISSN
- 2297-055X (ISSN-L)
- PMC
- PMC11270812
- OpenAlex
- W4400369011
- Cited by
- 57
- References
- 66
- Citations by year
- 2026: 29 · 2025: 27 · 2024: 1
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cardiovascular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, anti-inflammatory activity, C-reactive protein, type 2 diabetes, obesity, cardiovascular risk reduction, GLP-1 receptor agonists, inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.